Is NASDAQ:ETON suited for growth investing?

Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ETON PHARMACEUTICALS INC (NASDAQ:ETON) is suited for growth investing. Investors should of course do their own research, but we spotted ETON PHARMACEUTICALS INC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.

A Deep Dive into ETON PHARMACEUTICALS INC's Growth Metrics.

• The Return on Equity(ROE) of ETON PHARMACEUTICALS INC is 13.2%, which is a strong number. This indicates the company's ability to generate favorable returns for shareholders and reflects its effective management of resources.
• With a track record of beating EPS estimates in the last 4 quarters, ETON PHARMACEUTICALS INC showcases its consistent ability to deliver earnings surprises. This reflects the company's strong execution and its competitive position in the market.
• The 1-year revenue growth of ETON PHARMACEUTICALS INC (74.16%) has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and expand its market share.
• The q2q revenue growth of 118.0% of ETON PHARMACEUTICALS INC highlights the company's ability to generate incremental revenue and suggests positive market demand for its products or services.
• With a favorable trend in its operating margin over the past year, ETON PHARMACEUTICALS INC demonstrates its ability to enhance profitability through efficient operations. This growth reflects the company's focus on optimizing its cost structure.
• ETON PHARMACEUTICALS INC has experienced notable growth in its free cash flow (FCF) over the past year, signaling improved cash generation and strong financial performance. This growth suggests the company's ability to generate excess cash for reinvestment or shareholder returns.
• ETON PHARMACEUTICALS INC has shown positive momentum in its earnings per share (EPS) on a quarter-to-quarter (Q2Q) basis, with a 83.33% increase. This reflects the company's successful execution of its business strategies and its commitment to delivering improved financial results.
• ETON PHARMACEUTICALS INC has seen a 42.86% change in the average next Quarter EPS Estimate by analysts over the last 3 months, signaling the shifting perception of the company's EPS outlook.
• In the most recent financial report, ETON PHARMACEUTICALS INC reported a 83.33% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
• accelerating EPS growth for ETON PHARMACEUTICALS INC: the current Q2Q growth of 83.33% exceeds the previous year Q2Q growth of 50.0%.

What is the full fundamental picture of NASDAQ:ETON telling us.

ChartMill assigns a Fundamental Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple fundamental indicators and properties.

ETON gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 203 industry peers in the Pharmaceuticals industry. ETON has only an average score on both its financial health and profitability. ETON is not priced too expensively while it is growing strongly. Keep and eye on this one!

For an up to date full fundamental analysis you can check the fundamental report of ETON

Our Lois Navellier screen will find you more ideas suited for growth investing.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.